Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.

The FDA might only have two PDUFA dates on the calendar this week, but all eyes in the neurodegenerative disease community will be on the first one: Amylyx’s AMX0035 for ALS.

Sanofi and Regeneron Pharmaceuticals presented results Friday from the Phase III PRIME trial that showed Dupixent (dupilumab) strongly improves itching and skin lesions in adult patients with prurigo nodularis.

The European Union’s drugs regulator may be a few weeks from deciding whether to approve the experimental COVID-19 vaccine developed by French drugmaker Sanofi and its British partner GSK, a Sanofi executive said on Monday.

Although the treatment was once seen to have strong commercial potential in breast cancer, this second trial failure deals a major blow to the French healthcare company’s development prospects.

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill for prescription drugs in the United States.

Shares in GSK, Sanofi, Haleon, and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing concerns about U.S. litigation over a heartburn drug that was pulled from the market in 2020 for containing a probable carcinogen.

Global pharma giant Sanofi and Chinese company Innovent Biologics have penned a strategic partnership to develop and commercialize innovative treatments for patients with hard-to-treat cancers in China.

French healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.